If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
Logan Lutton
Advertisement
Logan Lutton is a contributing author for Medical Economics.
Articles by Logan Lutton
An alarming amount of COVID-19 disinformation is prevalent even from physicians.
An expected rise in COVID-19 cases in combination with other preventable diseases could overwhelm the healthcare system.
A new survey identifies what executives think could be the biggest disruptions in the next year for hospitals and health care groups.
Advertisement
Latest Updated Articles
How Will COVID-19 Disrupt Healthcare Going Forward?March 18th 2021
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5